Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response

Ocrelizumab is a B-cell-depleting monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and active primary progressive MS (aPPMS). This prospective, uncontrolled, open-label, observational study aimed to assess the efficacy of ocrelizumab in patients with aP...

Descripción completa

Detalles Bibliográficos
Autores principales: Boziki, Marina, Bakirtzis, Christos, Sintila, Styliani-Aggeliki, Kesidou, Evangelia, Gounari, Evdoxia, Ioakimidou, Aliki, Tsavdaridou, Vasiliki, Skoura, Lemonia, Fylaktou, Asimina, Nikolaidou, Vasiliki, Stangou, Maria, Nikolaidis, Ioannis, Giantzi, Virginia, Karafoulidou, Eleni, Theotokis, Paschalis, Grigoriadis, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222195/
https://www.ncbi.nlm.nih.gov/pubmed/35741088
http://dx.doi.org/10.3390/cells11121959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222195/
https://www.ncbi.nlm.nih.gov/pubmed/35741088
http://dx.doi.org/10.3390/cells11121959

Ejemplares similares